Ratio Therapeutics Radiopharmaceutical Manufacturing Facility

Radiopharmaceutical Therapies (RPTs) are specialized cancer treatments that use radioactive drugs to deliver radiation directly to tumor cells. By combining a radioactive isotope with a targeting molecule, these therapies destroy cancer cells while minimizing effects on healthy tissue.

Ratio Therapeutics’ mission to advance the development of best-in-class RPTs for cancer treatment is driving the establishment of a new radiopharmaceutical research and manufacturing facility. This center will be dedicated to producing next-generation treatments, supporting Ratio’s commitment to accelerating the discovery of radiotherapeutics for cancer patients.

The 38,000-square-foot radiopharmaceutical production facility is designed with future expansion in mind to address commercial needs. This facility will support the integration of Ratio’s current and future drugs, enabling efficient scaling of manufacturing as the company grows. The facility will benefit from the region’s robust radiopharmaceutical supply network and strategic proximity to an international airport, positioning Ratio to manage the complex supply chain and speed-to-market requirements.

This facility will be part of the Wasatch Group’s Medical Innovation Technology Research Campus, a hub for medical advancement.